Last updated 4 months ago
Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)
700 patients around the world
Available in Argentina, Chile, United States, Spain, Mexico, Colombia, Peru
Study duration will vary per participant in this event driven trial with a treatment duration
of approximately 12 to 60 months.
Sanofi
3Research sites
700Patients around the world
This study is for people with
Multiple sclerosis
Primary progressive multiple sclerosis
Requirements for the patient
To 55 Years
All Gender
Medical requirements
Sites
Libertad 836 - Libertad 836, Ciudad de Buenos Aireswww.idim.com.ar/
StudyPERSEUS
SponsorSanofi
Study typeInterventional
Conditions
Primary progressive multiple sclerosis
Requirements
To 55 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT04458051
